Evidence map›Paper›PMID 29313798›Full record

ReviewBlood transfusion = Trasfusione del sangue2018

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Piercarla Schinco, Giancarlo Castaman, Antonio Coppola, Dorina Cultrera, Cosimo Ettorre, Anna C Giuffrida, Emanuela Marchesini, Renato Marino, Marta Milan, Claudio Molinari and 3 more

Abstract readReview
In one paragraph

Review in Blood transfusion = Trasfusione del sangue, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Piercarla SchincoRRC Thrombosis & Haemophilia Centre, AOU "Città della Salute e della Scienza" - Molinette Hospital, Turin, Italy.
Giancarlo CastamanCentre for Bleeding Disorders, Careggi University Hospital, Florence, Italy.
Antonio CoppolaRegional Reference Centre for Coagulation Disorders, "Federico II" University Hospital, Naples, Italy.
Dorina CultreraDepartment of Haematology, Haemophilia Regional Reference Centre, University Hospital of Catania, Catania, Italy.
Cosimo EttorreHaemophilia and Thrombosis Centre, "Policlinico Giovanni XXIII", Bari, Italy.
Anna C GiuffridaHaemophilia Centre, Blood Transfusion Centre, University of Verona, Verona, Italy.
Emanuela MarchesiniDepartment of Vascular and Emergency Medicine, "Santa Maria della Misericordia" University Hospital, Perugia, Italy.
Renato MarinoHaemophilia and Thrombosis Centre, "Policlinico Giovanni XXIII", Bari, Italy.
Marta MilanDepartment of Cardiac Thoracic and Vascular Sciences, Haemophilia Centre Unit of Coagulopathies, University Hospital of Padua, Padua, Italy.
Claudio MolinariThrombosis and Haemostasis Unit, "Giannina Gaslini" Children's Hospital, Genoa, Italy.
Simona M Siboni"Angelo Bianchi Bonomi" Haemophilia and Thrombosis Centre, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano", Milan, Italy.
Ezio ZanonDepartment of Cardiac Thoracic and Vascular Sciences, Haemophilia Centre Unit of Coagulopathies, University Hospital of Padua, Padua, Italy.
Augusto B FedericiDivision of Haematology and Transfusion Medicine, "L. Sacco" University Hospital and Department of Oncology and Haematology Oncology, University of Milan, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in the care of von Willebrand's disease (vWD) have allowed the majority of patients to be managed adequately. Even in the more severe forms, it is now possible to control recurrent bleeding through secondary long-term prophylaxis with von Willebrand factor-containing concentrates. Moreover, in the setting of surgical prophylaxis, the combination of interdisciplinary management and close patient monitoring yields a positive outcome in nearly all cases, although safety concerns remain. In clinical practice, the effectiveness of therapy is hindered by the difficulties in making a rapid, yet accurate diagnosis, in identifying the subgroup of bleeders who may benefit most from a specific strategy, and in selecting the optimal product and regimen.Since specific guidelines for heavy bleeders requiring short- and long-term prophylaxis are still lacking, sharing the experience of experts dealing with vWD patients on a daily basis is crucial to fill gaps in information relating to patient management. To address this important issue, 13 Italian haematologists met in Milan on April, 2, 2016 and in Florence on July, 9, 2016. A 30-question survey constituted the input to discuss (i) optimisation of the diagnostic workflow for vWD, (ii) the characteristics of patients who may benefit from secondary long-term prophylaxis (in particular with the purified von Willebrand factor concentrate with a low content of factor VIII), (iii) the key elements to consider when selecting a concentrate and (iv) the pre-operative and post-operative management of vWD patients. A summary of the main points covered is provided in this report.

Indexed as

Congresses as TopicHumansItalyPractice Guidelines as Topicvon Willebrand Diseases

Identifiers

PMID29313798
PMCPMC6034771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.